亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Sequential trans-arterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy (START-FIT) for locally advanced hepatocellular carcinoma: A single-arm, phase II trial.

医学 肝细胞癌 临床终点 实体瘤疗效评价标准 肝功能 不利影响 中性粒细胞减少症 临床研究阶段 外科 放射科 内科学 胃肠病学 肿瘤科 泌尿科 临床试验 化疗
作者
Chi Leung Chiang,Wan Hang Keith Chiu,Wing Hang Lau,Sik-Kwan Chan,Ann Shing Lee,Feng-Ming Spring Kong,Albert Chi‐Yan Chan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 4091-4091 被引量:2
标识
DOI:10.1200/jco.2022.40.16_suppl.4091
摘要

4091 Background: Previous studies proposed therapeutic synergy between loco-regional therapies and checkpoint inhibitors in hepatocellular carcinoma (HCC). We aimed to study the safety and efficacy of sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by Avelumab in patients with locally advanced HCC. Methods: Patients with locally advanced HCC not suitable for curative resections were eligible. All patients had HCC ≥ 5cm, tumor nodules ≤3, and child-Pugh A5-B7 liver function. Tumors with distant metastasis, main portal vein (VP4) invasion, or inferior vena cava (VV3) invasion were excluded. Patients underwent single episode of TACE followed by 5-fraction SBRT (28 days afterwards), followed by Avelumab (10mg per kg) 14 days afterwards and every 2 weeks thereafter. The primary endpoint was percentage of patients amendable to curative surgery, defined as R0 resection with sufficient remnant liver volume and function. Secondary endpoints were objective response rate (ORR) per modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1, survivals, and treatment-related adverse event (TRAE). The sample size assumed that around 20% patients amendable to surgery after experimental treatment compared to 5% of historical institutional results after TACE. Modified Simon two-stage optimal design was used (power, 80%; a = 0.05; P0 = 0.05; P1 = 0.20; n1 = 10; n = 29 with an additional four patients to allow for drop-out or other reasons). Results: Out of 67 patients screened, 33 patients were enrolled. The median sum of diameter of lesion(s) was 15.1cm (range: 5.3-31.1cm), and 21 (63.6%) had marcrovascular invasion (n=13, hepatic vein, n=3 branched portal vein, n=5 both). After a median follow-up of 17.2 months (range: 3.5-31.6 months), 3 (9.1%) patients had tumor downstaged with curative surgery done. The objective response rate was 62.5% (95% CI, 45.3-77.1%), of whom 15 had complete response (CR) (43.8%) and 6 had partial response (18.7%). The median overall survival (OS) and progression-free survival was 30.3 months (95% CI: 22.7-37.8 months) and 20.7 months (95% CI: 14.6-26.8 months) respectively. All three patients with surgery done were alive at 2 years (100%). For 15 patients had CR, the 2-year OS rate was 92.9% without surgery. Ten patients (30.3%) experienced ≥ grade 3 TRAEs, commonly transient increase in alanine / aspartate aminotransferase (n=4, 12.1%) and bilirubin (n=2, 6%) level after TACE. Five patients (15.2 %) developed ≥ grade 3 immune-related adverse events. Conclusions: Although merely 9% of patients were downstaged to receive curative surgery, combined locoregional treatment and immunotherapy is safe and resulted in an unexpectedly high CR rate of 43% and median OS of 30 months in patients with locally advanced unresectable HCC. Clinical trial information: NCT 03817736.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
彭于晏的应助被椰子云采纳,获得10
刚刚
1秒前
1秒前
小蘑菇的应助被海藻采纳,获得10
2秒前
找找完成签到 ,获得积分10
5秒前
南宫雪发布了新的文献求助30
5秒前
9秒前
9秒前
9秒前
ding的应助被coco采纳,获得10
9秒前
Maestro_S的应助被纯情的阁采纳,获得10
12秒前
海藻发布了新的文献求助10
13秒前
omoily发布了新的文献求助10
13秒前
Coral369发布了新的文献求助10
15秒前
自信紫夏完成签到,获得积分10
16秒前
ze完成签到,获得积分10
22秒前
VT发布了新的文献求助10
27秒前
28秒前
30秒前
情怀的应助被肉包子采纳,获得10
33秒前
33秒前
852的应助被Hidos采纳,获得30
34秒前
34秒前
王老裂发布了新的文献求助10
35秒前
35秒前
36秒前
h11的应助被纯情的阁采纳,获得10
36秒前
ze发布了新的文献求助10
37秒前
37秒前
王老裂发布了新的文献求助10
38秒前
王老裂发布了新的文献求助10
38秒前
余铸海完成签到,获得积分10
39秒前
王老裂发布了新的文献求助10
39秒前
39秒前
清爽笙完成签到,获得积分10
40秒前
h11的应助被ming采纳,获得10
42秒前
EllenLawliet发布了新的文献求助10
45秒前
论文真难写的应助被LX有理想采纳,获得10
47秒前
爆米花的应助被EllenLawliet采纳,获得10
49秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277